Skip to main content
Clinical Trials/CTRI/2019/04/018434
CTRI/2019/04/018434
Not yet recruiting
Phase 3

Randomised, Double-Blind, Placebo- Controlled Trial Evaluating Safety and Efficacy of add-on Probiotic in Prevention of Recurrent Urinary Tract Infection in Adult Women

nique Biotech Linited0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: N328- Other specified disorders of bladder
Sponsor
nique Biotech Linited
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
nique Biotech Linited

Eligibility Criteria

Inclusion Criteria

  • i.Women of 18\-50 years of age who have not attained menopause
  • ii.Women with an active episode of recurrent UTI
  • iii.Recurrent UTI defined as:
  • a)More than 2 symptomatic, culture\-proven UTI over past 6 months OR
  • b)More than 3 symptomatic, culture\-proven UTI over past 12 months
  • iv.Willing to give informed consent for the study

Exclusion Criteria

  • i.Polycystic disease, interstitial cystitis, previous urological surgery, stones, or anatomical abnormalities of the urinary tract
  • ii.Pregnant or breastfeeding or planning a pregnancy in the next 6 months
  • iii.Known allergy or intolerance to any of the study products
  • iv.A history of renal stones and/or renal transplantation
  • v.Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes
  • vi.Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement
  • vii.Intermittent or indwelling catheterization

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Randomised, double blind, placebo-controlled, trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1ACharcot-Marie-Tooth disease type 1A (CMT1A)Nervous System DiseasesHereditary and idiopathic neuropathy
ISRCTN61074476niversity College London (UCL) and University College London Hospitals NHS Trust (UCLH) (UK)50
Recruiting
Phase 3
Investigation to assess whether Mi-Gel applied to the vulvar vestibule results in a reduction in pain with intercourse compared to a placeboentry dyspareuniaRenal and Urogenital - Other renal and urogenital disordersNeurological - Other neurological disorders
ACTRN12619001163190Women's Health & Research Institute of Australia80
Terminated
Phase 3
A Study to Compare Loperimide to Placebo for the Prevention of Excess Fluid Losses From the Stoma in Patients with New Loop Ileostomy.
ACTRN12614000180617Hunter New England Local Health District86
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyAcute heart failure with iron deficiencyMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-001467-36-PLVifor (International) Inc.650
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiency
EUCTR2016-001467-36-NLVifor (International) Inc.1,110